RecruitingPhase 2NCT06257394

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hyoung Jin Kang
Intervention
Dasatinib(Sprycel) arm(drug)
Enrollment
74 target
Eligibility
1-19 years · All sexes
Timeline
20242034

Study locations (6)

Collaborators

Asan Medical Center · Samsung Medical Center · Severance Hospital · Pusan National University Yangsan Hospital · Seoul St. Mary's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06257394 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials